Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York 10032-3784, USA.
J Pharmacol Exp Ther. 2010 Jun;333(3):736-47. doi: 10.1124/jpet.110.166884. Epub 2010 Mar 22.
Hepatic ischemia reperfusion (IR) injury causes acute kidney injury (AKI). However, the contribution of AKI to the pathogenesis of liver IR injury is unclear. Furthermore, controversy still exists regarding the role of A(1) adenosine receptors (A(1)ARs) in AKI. In this study, we determined whether exogenous and endogenous A(1)AR activation protects against AKI with subsequent liver protection after hepatic IR in mice. We found that after hepatic IR A(1) knockout (KO) mice and A(1)AR antagonist-treated A(1) wild-type (WT) mice developed worse AKI and liver injury compared with vehicle-treated A(1)WT mice. Moreover, a selective A(1)AR agonist protected against hepatic IR-induced AKI and liver injury in A(1)WT mice. Renal A(1)AR-mediated kidney protection plays a crucial role in protecting the liver after IR because: 1) selective unilateral renal lentiviral overexpression of human A(1)ARs [enhanced green fluorescent protein (EGFP)-huA(1)AR] in A(1)KO mice protected against both kidney and liver injury sustained after liver IR, 2) removal of the EGFP-huA(1)AR lentivirus-injected kidney from A(1)KO mice abolished both renal and hepatic protection after liver IR, and 3) bilateral nephrectomy before hepatic ischemia abolished the protective effects of A(1)AR activation in A(1)WT mice. Finally, inhibition of Akt, but not extracellular signal-regulated kinase mitogen-activated protein kinase, prevented the kidney and liver protection afforded by A(1)AR agonist treatment. Taken together, we show that endogenous and exogenous activation of renal A(1)ARs protect against liver and kidney injury after liver IR in vivo via pathways involving Akt activation.
肝缺血再灌注 (IR) 损伤可导致急性肾损伤 (AKI)。然而,AKI 在肝 IR 损伤发病机制中的作用尚不清楚。此外,A(1)腺苷受体 (A(1)ARs) 在 AKI 中的作用仍存在争议。在这项研究中,我们确定了外源性和内源性 A(1)AR 激活是否可在肝 IR 后通过保护肾脏来防止 AKI,并进一步保护肝脏。我们发现,肝 IR 后 A(1)敲除 (KO) 小鼠和 A(1)AR 拮抗剂处理的 A(1)野生型 (WT) 小鼠与载体处理的 A(1)WT 小鼠相比,发生更严重的 AKI 和肝损伤。此外,选择性 A(1)AR 激动剂可防止 A(1)WT 小鼠发生肝 IR 诱导的 AKI 和肝损伤。肾脏 A(1)AR 介导的肾脏保护在 IR 后保护肝脏方面发挥着至关重要的作用,原因在于:1)在 A(1)KO 小鼠中,单侧肾脏慢病毒过表达人 A(1)ARs [增强型绿色荧光蛋白 (EGFP)-huA(1)AR] 可保护肝 IR 后发生的肾脏和肝脏损伤,2)从 A(1)KO 小鼠中去除 EGFP-huA(1)AR 慢病毒注射肾脏可消除肝 IR 后肾脏和肝脏的保护作用,3)肝缺血前双侧肾切除术可消除 A(1)WT 小鼠中 A(1)AR 激活的保护作用。最后,Akt 抑制而非细胞外信号调节激酶丝裂原激活蛋白激酶抑制可防止 A(1)AR 激动剂治疗所带来的肾脏和肝脏保护作用。总之,我们证明了内源性和外源性激活肾脏 A(1)AR 可通过涉及 Akt 激活的途径防止肝 IR 后体内的肝和肾损伤。